Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping …
S Lu, J Fang, X Li, L Cao, J Zhou, Q Guo… - The Lancet …, 2021 - thelancet.com
Background Savolitinib is a selective MET tyrosine-kinase inhibitor. We investigated the
activity and safety of savolitinib in patients with pulmonary sarcomatoid carcinoma and other …
activity and safety of savolitinib in patients with pulmonary sarcomatoid carcinoma and other …
Pulmonary sarcomatoid carcinoma: progress, treatment and expectations
X Li, D Wu, H Liu, J Chen - Therapeutic Advances in …, 2020 - journals.sagepub.com
Pulmonary sarcomatoid carcinoma (PSC) is a unique, highly invasive pulmonary
malignancy with a poor prognosis, representing 0.1–0.4% of all malignant lung tumors …
malignancy with a poor prognosis, representing 0.1–0.4% of all malignant lung tumors …
Approaches to tumor classification in pulmonary sarcomatoid carcinoma
C Baldovini, G Rossi, A Ciarrocchi - Lung Cancer: Targets and …, 2019 - Taylor & Francis
Pulmonary sarcomatoid carcinoma (PSC) is a heterogeneous category of primary lung
cancer accounting from 0.3% to 3% of all primary lung malignancies. According to the most …
cancer accounting from 0.3% to 3% of all primary lung malignancies. According to the most …
Next-Generation Sequencing of Pulmonary Sarcomatoid Carcinoma Reveals High Frequency of Actionable MET Gene Mutations
Purpose To further understand the molecular pathogenesis of pulmonary sarcomatoid
carcinoma (PSC) and develop new therapeutic strategies in this treatment-refractory …
carcinoma (PSC) and develop new therapeutic strategies in this treatment-refractory …
[HTML][HTML] Pulmonary sarcomatoid carcinomas commonly harbor either potentially targetable genomic alterations or high tumor mutational burden as observed by …
AB Schrock, SD Li, GM Frampton, J Suh… - Journal of Thoracic …, 2017 - Elsevier
Introduction Pulmonary sarcomatoid carcinoma (PSC) is a high-grade NSCLC characterized
by poor prognosis and resistance to chemotherapy. Development of targeted therapeutic …
by poor prognosis and resistance to chemotherapy. Development of targeted therapeutic …
Efficacy of immune checkpoint inhibitors in lung sarcomatoid carcinoma
C Domblides, K Leroy, I Monnet, J Mazières… - Journal of Thoracic …, 2020 - Elsevier
Abstract Introduction Immune checkpoint inhibitors (ICIs) have improved cancer prognosis
but have not been evaluated specifically in sarcomatoid carcinoma (SC), a rare lung cancer …
but have not been evaluated specifically in sarcomatoid carcinoma (SC), a rare lung cancer …
[HTML][HTML] Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1) and strong immune-cell infiltration by TCD3 cells and macrophages
T Vieira, M Antoine, C Hamard, V Fallet, M Duruisseaux… - Lung Cancer, 2016 - Elsevier
Objectives Pulmonary sarcomatoid carcinomas (SC) are rare tumors, associated with worse
prognosis and resistant to platinum-based regimens. Therapies targeting the PD-1/PD-L1 …
prognosis and resistant to platinum-based regimens. Therapies targeting the PD-1/PD-L1 …
Sarcomatoid carcinoma of the lung: the Mayo Clinic experience in 127 patients
K Maneenil, Z Xue, M Liu, J Boland, F Wu… - Clinical lung cancer, 2018 - Elsevier
Background Pulmonary sarcomatoid carcinoma (PSC) is an unusual form of non–small-cell
lung cancer (NSCLC). Because of its rarity and heterogeneity, the treatment and prognosis …
lung cancer (NSCLC). Because of its rarity and heterogeneity, the treatment and prognosis …
[HTML][HTML] High co-expression of PD-L1 and HIF-1α correlates with tumour necrosis in pulmonary pleomorphic carcinoma
YL Chang, CY Yang, MW Lin, CT Wu… - European Journal of …, 2016 - Elsevier
Abstract Background Pulmonary pleomorphic carcinomas (PPCs) are uncommon malignant
tumours characterised by an aggressive clinical course and poor survival. These neoplasms …
tumours characterised by an aggressive clinical course and poor survival. These neoplasms …
Characteristics and clinical outcomes of sarcomatoid carcinoma of the lung
M Ung, I Rouquette, T Filleron, K Taillandy… - Clinical lung cancer, 2016 - Elsevier
Background Sarcomatoid carcinoma is a rare subtype of non–small-cell lung cancer, which
has aggressive behavior. We present information on the clinicopathologic characteristics …
has aggressive behavior. We present information on the clinicopathologic characteristics …